|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bernthal NM, Federman N, Eilber FR, Nelson
SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25
years) of a randomized, prospective clinical trial evaluating
chemotherapy in patients with high-grade, operable osteosarcoma.
Cancer. 118:5888–5893. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Grignani G, Palmerini E, Dileo P, Asaftei
SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F,
Casali PG, et al: A phase II trial of sorafenib in relapsed and
unresectable high-grade osteosarcoma after failure of standard
multimodal therapy: An Italian Sarcoma Group study. Ann Oncol.
23:508–516. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhang Y, Yang J, Zhao N, Wang C, Kamar S,
Zhou Y, He Z, Yang J, Sun B, Shi X, et al: Progress in the
chemotherapeutic treatment of osteosarcoma. Oncol Lett.
16:6228–6237. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Grignani G, Palmerini E, Ferraresi V,
D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y,
Sangiolo D, Marchesi E, et al: Italian Sarcoma Group: Sorafenib and
everolimus for patients with unresectable high-grade osteosarcoma
progressing after standard treatment: A non-randomised phase 2
clinical trial. Lancet Oncol. 16:98–107. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Filipek A and Kuźnicki J: Molecular
cloning and expression of a mouse brain cDNA encoding a novel
protein target of calcyclin. J Neurochem. 70:1793–1798.
1998.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Filipek A and Wojda U: p30, a novel
protein target of mouse calcyclin (S100A6). Biochem J. 320:585–587.
1996.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Topolska-Woś AM, Chazin WJ and Filipek A:
CacyBP/SIP - Structure and variety of functions. Biochim Biophys
Acta. 1860:79–85. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhai H, Shi Y, Jin H, Li Y, Lu Y, Chen X,
Wang J, Ding L, Wang X and Fan D: Expression of calcyclin-binding
protein/Siah-1 interacting protein in normal and malignant human
tissues: An immunohistochemical survey. J Histochem Cytochem.
56:765–772. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shi H, Gao Y, Tang Y, Wu Y, Gong H, Du J,
Zheng B, Hu J, Shi Q and Yu R: CacyBP/SIP protein is important for
the proliferation of human glioma cells. IUBMB Life. 66:286–291.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Rosińska S, Leśniak W and Filipek A:
Distinct effect of CacyBP/SIP on the ERK1/2-CREB-BDNF pathway in
undifferentiated and differentiated neuroblastoma NB2a cells.
Neurochem Int. 97:65–72. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen X, Zheng P, Xue Z, Li J, Wang W, Chen
X, Xie F, Yu Z and Ouyang X: CacyBP/SIP enhances multidrug
resistance of pancreatic cancer cells by regulation of P-gp and
Bcl-2. Apoptosis. 18:861–869. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fu C, Wan Y, Shi H, Gong Y, Wu Q, Yao Y,
Niu M, Li Z and Xu K: Expression and regulation of CacyBP/SIP in
chronic lymphocytic leukemia cell balances of cell proliferation
with apoptosis. J Cancer Res Clin Oncol. 142:741–748.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhai H, Shi Y, Chen X, Wang J, Lu Y, Zhang
F, Liu Z, Lei T and Fan D: CacyBP/SIP promotes the proliferation of
colon cancer cells. PLoS One. 12(e0169959)2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ning X, Sun S, Hong L, Liang J, Liu L, Han
S, Liu Z, Shi Y, Li Y, Gong W, et al: Calcyclin-binding protein
inhibits proliferation, tumorigenicity, and invasion of gastric
cancer. Mol Cancer Res. 5:1254–1262. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sun S, Ning X, Liu J, Liu L, Chen Y, Han
S, Zhang Y, Liang J, Wu K and Fan D: Overexpressed CacyBP/SIP leads
to the suppression of growth in renal cell carcinoma. Biochem
Biophys Res Commun. 356:864–871. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Topolska-Woś AM, Rosińska S and Filipek A:
MAP kinase p38 is a novel target of CacyBP/SIP phosphatase. Amino
Acids. 49:1069–1076. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Δ Δ C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chai R, Yu X, Tu S and Zheng B: Depletion
of UBA protein 2-like protein inhibits growth and induces apoptosis
of human colorectal carcinoma cells. Tumour Biol. 37:13225–13235.
2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Henderson T, Chen M, Darrow MA, Li CS,
Chiu CL, Monjazeb AM, Murphy WJ and Canter RJ: Alterations in
cancer stem-cell marker CD44 expression predict oncologic outcome
in soft-tissue sarcomas. J Surg Res. 223:207–214. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Comprehensive and Integrated Genomic
Characterization of Adult Soft Tissue Sarcomas. Cell 171:
950-965.e928, 2017.
|
|
22
|
Hartigan JA and Wong MA: A K-means
clustering algorithm. Appl Stat. 28:100–108. 2013.
|
|
23
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348.
2001.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Vats P, Ray K, Majumadar D, Amitabh Joseph
DA, Bayen S, Akunov A, Sarbaev A and Singh SB: Changes in
cardiovascular functions, lipid profile, and body composition at
high altitude in two different ethnic groups. High Alt Med Biol.
14:45–52. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhai HH, Meng J, Wang JB, Liu ZX, Li YF
and Feng SS: CacyBP/SIP nuclear translocation induced by gastrin
promotes gastric cancer cell proliferation. World J Gastroenterol.
20:10062–10070. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ning X, Sun S, Zhang K, Liang J, Chuai Y,
Li Y and Wang X: S100A6 protein negatively regulates
CacyBP/SIP-mediated inhibition of gastric cancer cell proliferation
and tumorigenesis. PLoS One. 7(e30185)2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang Y, Wang S, Qian W, Ji D, Wang Q,
Zhang Z, Wang S, Ji B, Fu Z and Sun Y: uc.338 targets p21 and
cyclin D1 via PI3K/AKT pathway activation to promote cell
proliferation in colorectal cancer. Oncol Rep. 40:1119–1128.
2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Merli M, Benassi MS, Gamberi G, Ragazzini
P, Sollazzo MR, Molendini L, Magagnoli G, Ferrari C, Maltarello MC
and Picci P: Expression of G1 phase regulators in MG-63
osteosarcoma cell line. Int J Oncol. 14:1117–1121. 1999.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Adams PD, Sellers WR, Sharma SK, Wu AD,
Nalin CM and Kaelin WG Jr: Identification of a cyclin-cdk2
recognition motif present in substrates and p21-like
cyclin-dependent kinase inhibitors. Mol Cell Biol. 16:6623–6633.
1996.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Song Z, Lin J, Sun Z, Ni J and Sha Y:
RNAi-mediated downregulation of CDKL1 inhibits growth and
colony-formation ability, promotes apoptosis of human melanoma
cells. J Dermatol Sci. 79:57–63. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
el-Deiry WS, Tokino T, Velculescu VE, Levy
DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and
Vogelstein B: WAF1, a potential mediator of p53 tumor suppression.
Cell. 75:817–825. 1993.PubMed/NCBI View Article : Google Scholar
|
